Skull Base Meningiomas: Is Surgical Resection Enough? Outcome Evaluation and Prognostic Factors Analysis in a Single-Center Cohort

Abstract

Background Surgical resection represents the mainstay of treatment in skull base meningiomas (SBMs). Considering the high recurrence rate reported, an adjuvant radiation therapy (RT) treatment should be considered. The aim of this study was to evaluate the progression-free survival (PFS), overall survival (OS), and prognostic factors conditioning outcome.

Methods Patients receiving surgical resection for grade I SBMs were included. The extent of resection (EOR) was dichotomized as gross total resection (GTR) and subtotal resection (STR). RT was administered only in patients receiving STR. Clinical outcome was evaluated by brain magnetic resonance imaging (MRI) performed every 6 months for the first year and yearly thereafter.

Results From January 2000 to December 2015, 123 patients were treated. The majority were females (70.7%), with a Karnofsky Performance Score (KPS) ≥80 (95%), and symptoms at diagnosis (91%). GTR was performed in 30% of cases and STR in 70%. RT was performed in 18 (20.9%) patients at diagnosis and in 29 (33.7%) patients at progression. Improvement or stability of neurologic status was obtained in 78.9% of patients. The median follow-up time was 91 months (range: 40–230 months). Local recurrence occurred in 34 (27.6%) patients at a median time of 45 months (range: 6–214 months). The median, 2-, 5-, and 10-year PFS were 193 months, 89.3, 81.8, and 72.5%, respectively. On univariate and multivariate analyses, factors impacting on PFS were EOR, tumor location, neurologic postoperative status, and adjuvant RT in STR.

Conclusions A safe surgical resection followed by RT adjuvant treatment could represent the better choice to obtain local control maintaining neurologic integrity. Our data underlined the value of adjuvant RT in incompletely resected meningiomas.

Keywords

skull base meningiomas - surgery - prognostic factors

Author Contribution

FP and PN performed most of the study and drafted the manuscript. FS and MS contributed to the conception of this study. ZF, EC, and MS participated in the acquisition of the data, and LP and MF assisted in the interpretation of the results.

Publication History

Received: 01 July 2020

Accepted: 23 April 2021

Article published online:
12 December 2021

• References

• 1 Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery 2005; 57 (06) 1088-1095 , discussion 1088–1095
• 2 Rohringer M, Sutherland GR, Louw DF, Sima AA. Incidence and clinicopathological features of meningioma. J Neurosurg 1989; 71 (5, Pt 1): 665-672
• 3 Goldbrunner R, Minniti G, Preusser M. et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 2016; 17 (09) e383-e391
• 4 Alvernia JE, Dang ND, Sindou MP. Convexity meningiomas: study of recurrence factors with special emphasis on the cleavage plane in a series of 100 consecutive patients. J Neurosurg 2011; 115 (03) 491-498
• 5 Ohba S, Kobayashi M, Horiguchi T. et al. Long-term surgical outcome and biological prognostic factors in patients with skull base meningiomas. J Neurosurg 2011; 114 (05) 1278-1287
• 6 Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20 (01) 22-39
• 7 Pessina F, Navarria P, Clerici E. et al. Intracranial meningiomas: a systematic analysis of prognostic factors for recurrence in a large single institution surgical series. World Neurosurg 2019; 123: e273-e279
• 8 Mansouri A, Klironomos G, Taslimi S. et al. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. J Neurosurg 2016; 125 (02) 431-440
• 9 Savardekar AR, Patra DP, Bir S. et al. Differential tumor progression patterns in skull base versus non-skull base meningiomas: a critical analysis from a long-term follow-up study and review of literature. World Neurosurg 2018; 112: e74-e83
• 10 Nanda A, Bir SC, Maiti TK, Konar SK, Missios S, Guthikonda B. Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. J Neurosurg 2017; 126 (01) 201-211
• 11 Cornelius JF, Slotty PJ, Steiger HJ, Hänggi D, Polivka M, George B. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir (Wien) 2013; 155 (03) 407-413
• 12 Komotar RJ, Iorgulescu JB, Raper DM. et al. The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg 2012; 117 (04) 679-686
• 13 Mair R, Morris K, Scott I, Carroll TA. Radiotherapy for atypical meningiomas. J Neurosurg 2011; 115 (04) 811-819
• 14 Rogers L, Zhang P, Vogelbaum MA. et al. Intermediate-risk meningioma: initial outcomes from NRG oncology RTOG 0539. J Neurosurg 2018; 129 (01) 35-47
• 15 Tanzler E, Morris CG, Kirwan JM, Amdur RJ, Mendenhall WM. Outcomes of WHO Grade I meningiomas receiving definitive or postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79 (02) 508-513
• 16 Goldsmith BM, Campos JM. Comparison of urine dipstick, microscopy, and culture for the detection of bacteriuria in children. Clin Pediatr (Phila) 1990; 29 (04) 214-218
• 17 Miao Y, Lu X, Qiu Y, Jiang J, Lin Y. A multivariate analysis of prognostic factors for health-related quality of life in patients with surgically managed meningioma. J Clin Neurosci 2010; 17 (04) 446-449
• 18 Saraf S, McCarthy BJ, Villano JL. Update on meningiomas. Oncologist 2011; 16 (11) 1604-1613
• 19 Kalbfleisch JD, Prentice RL. Marginal likelihoods based on Cox's regression and life model. Biometrika 1973; 60 (02) 267-278
• 20 McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg 2010; 112 (05) 925-933
• 21 Ayerbe J, Lobato RD, de la Cruz J. et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir (Wien) 1999; 141 (09) 921-932
• 22 Pieper DR, Al-Mefty O. Management of intracranial meningiomas secondarily involving the infratemporal fossa: radiographic characteristics, pattern of tumor invasion, and surgical implications. Neurosurgery 1999; 45 (02) 231-237 , discussion 237–238
• 23 van der Vossen S, Schepers VP, Berkelbach van der Sprenkel JW, Visser-Meily JM, Post MW. Cognitive and emotional problems in patients after cerebral meningioma surgery. J Rehabil Med 2014; 46 (05) 430-437
• 24 Lee KD, DePowell JJ, Air EL, Dwivedi AK, Kendler A, McPherson CM. Atypical meningiomas: is postoperative radiotherapy indicated?. Neurosurg Focus 2013; 35 (06) E15
• 25 Sughrue ME, Kane AJ, Shangari G. et al. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg 2010; 113 (05) 1029-1035
• 26 Olar A, Wani KM, Wilson CD. et al. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. Acta Neuropathol 2017; 133 (03) 431-444
• 27 Sahm F, Schrimpf D, Stichel D. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 2017; 18 (05) 682-694